MTEM - Molecular Templates Inc Stock Price, Fair Value and News

1.65USD-0.02 (-1.20%)Delayed as of 06 May 2024, 12:53 pm ET

Market Summary

USD1.65-0.02

Delayedas of 06 May 2024, 12:53 pm

-1.20%

MTEM Alerts

1 major insider buys recently.

MTEM Stock Price

View Fullscreen

MTEM RSI Chart

MTEM Valuation

Market Cap

11.0M

Price/Earnings (Trailing)

-1.35

Price/Sales (Trailing)

0.19

EV/EBITDA

-0.66

Price/Free Cashflow

-0.26

MTEM Price/Sales (Trailing)

MTEM Profitability

EBT Margin

-14.20%

Return on Equity

-192.88%

Return on Assets

-22.96%

Free Cashflow Yield

-382.17%

MTEM Fundamentals

MTEM Revenue

Revenue (TTM)

57.3M

Rev. Growth (Yr)

168.71%

Rev. Growth (Qtr)

3.24%

MTEM Earnings

Earnings (TTM)

-8.1M

Earnings Growth (Yr)

82.08%

Earnings Growth (Qtr)

4.94%

Breaking Down MTEM Revenue

52 Week Range

0.399.15

(Low)(High)

Last 7 days

-0.6%

Last 30 days

-5.6%

Last 90 days

-53.8%

Trailing 12 Months

304.8%

How does MTEM drawdown profile look like?

MTEM Financial Health

Current Ratio

0.97

Debt/Equity

8.64

Debt/Cashflow

-1.15

MTEM Investor Care

Shares Dilution (1Y)

75.25%

Diluted EPS (TTM)

-4.57

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	47.9M	50.3M	52.9M	57.3M
2022	44.0M	33.2M	35.1M	19.8M
2021	17.9M	26.1M	24.2M	38.7M
2020	19.4M	20.9M	21.5M	18.8M
2019	19.8M	23.9M	20.8M	22.3M
2018	2.0M	3.3M	9.4M	13.3M
2017	2.3M	2.6M	3.0M	3.4M
2016	0	0	39.4M	1.9M
2015	14.7M	14.7M	14.7M	76.9M
2014	13.3M	13.8M	14.3M	14.7M
2013	8.5M	9.9M	11.3M	12.5M
2012	1.3M	2.6M	3.9M	5.9M
2011	0	0	0	62.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Molecular Templates Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	biotech target n v	bought	587,500	2.35	250,000	-
Apr 02, 2024	lalande kevin m.	acquired	411,250	2.35	175,000	-
Jul 17, 2023	biotech target n v	bought	2,000,000	0.47	4,255,320	-
Jul 07, 2022	kim jason s.	acquired	8,583	0.71	12,089	see remarks
Jun 16, 2022	mclennan sean	bought	24,477	0.8159	30,000	see remarks
Jun 15, 2022	shv management services, llc	bought	55,180	0.89	62,000	-
Jun 15, 2022	lalande kevin m.	bought	55,180	0.89	62,000	-
Jun 14, 2022	lalande kevin m.	bought	52,200	0.87	60,000	-
Jun 14, 2022	shv management services, llc	bought	52,200	0.87	60,000	-
Jun 13, 2022	shv management services, llc	bought	91,000	0.91	100,000	-

Which funds bought or sold MTEM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	-3.00	5.00	-%
Apr 23, 2024	ARCADIA INVESTMENT MANAGEMENT CORP/MI	unchanged	-	-9.00	14.00	-%
Apr 18, 2024	Capital Advisors, Ltd. LLC	new	-	-	-	-%
Apr 16, 2024	TSFG, LLC	unchanged	-	-	-	-%
Apr 15, 2024	PFS Partners, LLC	unchanged	-	-4,967	7,466	-%
Mar 11, 2024	VANGUARD GROUP INC	added	13.53	-230,775	468,574	-%
Feb 29, 2024	Tortoise Investment Management, LLC	unchanged	-	-16.00	22.00	-%
Feb 26, 2024	Virtu Financial LLC	new	-	39,000	39,000	-%
Feb 15, 2024	BARCLAYS PLC	new	-	1,000	1,000	-%

Are Funds Buying or Selling MTEM?

Are funds buying MTEM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MTEM

No. of Funds

MTEM Alerts

1 major insider buys recently.

Unveiling Molecular Templates Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 29, 2024	longitude capital partners iii, llc	4.6%	309,819	SC 13D/A
Apr 02, 2024	sante health ventures i lp	6.2%	407,773	SC 13D/A
Feb 14, 2024	silverarc capital management, llc	6.60%	354,608	SC 13G
Feb 14, 2024	k2 healthventures equity trust llc	985%	596,145	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	5.4%	289,378	SC 13G/A
Feb 14, 2024	lytton laurence w	4.3%	232,951	SC 13G/A
Feb 13, 2024	bb biotech ag	19.2%	1	SC 13G/A
Oct 24, 2023	longitude capital partners iii, llc	5.7%	309,819	SC 13D/A
Jul 20, 2023	lytton laurence w	5.1%	4,142,361	SC 13G
Jul 18, 2023	adage capital partners gp, l.l.c.	5.45%	4,391,489	SC 13G

Recent SEC filings of Molecular Templates Inc

View All Filings

Date Filed	Form Type	Document
May 03, 2024	424B3	Prospectus Filed
Apr 29, 2024	SC 13D/A	13D - Major Acquisition
Apr 25, 2024	10-K/A	Annual Report
Apr 25, 2024	S-3	S-3
Apr 12, 2024	8-K	Current Report
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 02, 2024	SC 13D/A	13D - Major Acquisition
Mar 29, 2024	10-K	Annual Report
Mar 29, 2024	8-K	Current Report

Peers (Alternatives to Molecular Templates Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.83	14.43	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.1	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.84	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

Molecular Templates Inc News

Latest updates

Molecular Templates Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	3.2%	7,016,000	6,796,000	6,865,000	36,629,000	2,611,000	4,240,000	4,417,000	8,486,000	17,964,000	2,379,000	15,134,000	3,220,000	3,497,000	4,298,000	6,909,000	4,141,000	6,197,000	3,618,000	5,447,000	7,008,000	4,684,000
Operating Expenses	3.8%	12,387,000	11,933,000	18,608,000	24,844,000	23,670,000	27,907,000	27,931,000	29,117,000	27,265,000	31,908,000	30,049,000	29,549,000	29,414,000	27,169,000	36,826,000	26,278,000	22,601,000	41,881,000	14,848,000	13,389,000	11,479,000
S&GA Expenses	-16.7%	3,591,000	4,309,000	5,195,000	5,802,000	6,080,000	5,934,000	6,566,000	7,620,000	7,952,000	9,027,000	8,922,000	8,181,000	7,116,000	7,547,000	6,412,000	5,647,000	6,028,000	4,509,000	4,605,000	4,935,000	3,916,500
R&D Expenses	15.4%	8,796,000	7,624,000	13,413,000	19,042,000	17,590,000	21,973,000	21,365,000	21,497,000	19,313,000	22,881,000	21,127,000	21,368,000	22,298,000	19,622,000	30,414,000	20,631,000	16,573,000	15,249,000	10,243,000	8,454,000	7,562,500
EBITDA Margin	104.7%	0.01	-0.30	-0.69	-1.02	-4.14	-2.00	-2.30	-1.55	-1.92	-3.85	-3.32	-5.79	-5.31	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	1,182,000	1,111,000	1,024,000	915,000	803,000	753,000	767,000	756,000	408,000	317,000	320,000	363,000	85,000	163,000	170,000	170,000	170,000	174,000	272,000
Income Taxes	-	-	-	-	-	27,000	26,000	-	-	-	-	-	-	-	-	-	5,000	-	-	-	-	-
Earnings Before Taxes	4.7%	-3,959,000	-4,153,000	-10,868,000	10,845,000	-22,022,000	-24,612,000	-24,420,000	-21,611,000	-10,243,000	-30,387,000	-15,601,000	-26,778,000	-28,445,000	-23,225,000	-31,228,000	-22,013,000	-15,881,000	-38,219,000	-9,153,000	-6,168,000	-
EBT Margin	71.3%	-0.14	-0.50	-0.93	-1.26	-4.69	-2.30	-2.61	-1.77	-2.15	-4.18	-3.60	-6.12	-5.57	-	-	-	-	-	-	-	-
Net Income	4.9%	-3,948,000	-4,153,000	-10,868,000	10,845,000	-22,033,500	-24,638,000	-24,451,000	-21,611,000	-10,243,000	-30,387,000	-15,601,000	-26,778,000	-28,445,000	-23,225,000	-31,228,000	-22,018,000	-15,881,000	-38,219,000	-9,153,000	-6,168,000	-6,634,000
Net Income Margin	71.4%	-0.14	-0.50	-0.93	-1.26	-4.69	-2.31	-2.61	-1.77	-2.15	-4.18	-3.60	-6.12	-5.57	-	-	-	-	-	-	-	-
Free Cashflow	29.8%	-5,287,000	-7,534,000	-9,655,000	-19,544,000	-18,744,000	-25,413,000	-19,816,000	-28,249,000	-23,344,000	-26,133,000	-26,685,000	41,779,000	-24,386,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-19.7%	35.00	44.00	36.00	79.00	98.00	119	141	163	192	218	245	252	140	169	142	161	174	93.00	131	141	146
Current Assets	-26.1%	17.00	23.00	12.00	52.00	68.00	87.00	111	132	148	177	205	209	99.00	130	108	124	140	64.00	80.00	91.00	105
Cash Equivalents	-27.1%	12.00	16.00	5.00	39.00	32.00	22.00	27.00	20.00	25.00	28.00	43.00	99.00	25.00	33.00	28.00	34.00	85.00	15.00	17.00	38.00	88.00
Net PPE	-13.8%	7.00	9.00	10.00	13.00	15.00	16.00	18.00	19.00	19.00	20.00	21.00	22.00	22.00	21.00	20.00	19.00	18.00	14.00	9.00	7.00	7.00
Liabilities	-16.3%	31.00	37.00	44.00	80.00	113	114	115	116	127	146	147	143	81.00	85.00	87.00	77.00	71.00	40.00	42.00	44.00	5.00
Current Liabilities	-19.5%	17.00	22.00	27.00	30.00	57.00	50.00	46.00	45.00	47.00	47.00	45.00	77.00	38.00	40.00	41.00	44.00	36.00	24.00	26.00	28.00	33.00
Long Term Debt	-	-	-	-	36.00	36.00	36.00	36.00	36.00	35.00	35.00	35.00	15.00	15.00	15.00	15.00	3.00	3.00	3.00	3.00	3.00	3.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	36.00	36.00	36.00	36.00	36.00	35.00	35.00	35.00	15.00	15.00	15.00	15.00	3.00	3.00	3.00	3.00	3.00	3.00
Shareholder's Equity	-38.1%	4.00	7.00	-	-	-15.13	4.00	26.00	47.00	66.00	72.00	97.00	108	59.00	84.00	56.00	84.00	103	53.00	89.00	96.00	101
Retained Earnings	-0.9%	-452	-448	-444	-433	-444	-422	-398	-373	-352	-341	-311	-295	-269	-240	-217	-186	-164	-148	-110	-100	-94.70
Additional Paid-In Capital	0.3%	457	456	436	432	430	427	424	421	418	414	409	404	328	325	273	270	267	201	199	197	196
Shares Outstanding	0%	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	-	-	-	-	-	-	-	-
Float	-	-	-	18.00	-	-	-	29.00	-	-	-	266	-	-	-	410	-	-	-	168	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	29.8%	-5,287	-7,534	-9,638	-19,361	-18,432	-24,427	-18,469	-27,696	-22,461	-24,810	-25,330	42,214	-21,506	-19,818	-24,324	-18,149	14,028	-16,394	-11,902	-10,976	19,394
Share Based Compensation	9.0%	1,360	1,248	1,784	2,310	2,604	2,641	2,982	3,682	3,809	4,243	4,513	4,066	3,290	3,285	3,050	2,192	1,529	1,527	1,443	1,360	1,230
Cashflow From Investing	-111.1%	-1.00	9.00	3,134	25,953	28,345	19,580	26,107	21,285	19,813	8,457	-50,323	-40,387	13,206	-22,592	7,674	-32,951	-8,220	14,383	-9,967	-35,920	-10,524
Cashflow From Financing	-100.0%	-	18,384	-	-	-	9.00	-274	-	38.00	856	19,957	71,741	108	48,618	10,076	93.00	64,375	484	809	30.00	107

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MTEM Income Statement

2023-12-31

Consolidated Statement of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total revenue	$ 57,306	$ 19,754
Operating expenses:
Research and development	48,875	82,425
General and administrative	18,897	26,200
Total operating expenses	67,772	108,625
Loss from operations	10,466	88,871
Interest and other income, net	1,208	988
Interest and other expense, net	(2,654)	(4,716)
Gain on extinguishment of debt	1,795
Change in valuation of contingent value right (Note 4)	2,457
Loss on disposal of property and equipment	(475)	(66)
Loss before provision (benefit) for income taxes	8,135	92,665
Provision (benefit) for income taxes	(11)	53
Net loss attributable to common shareholders	$ 8,124	$ 92,718
Net loss per share attributable to common shareholders:
Basic (in dollars per share)	$ 1.80	$ 24.69
Diluted (in dollars per share)	$ 1.80	$ 24.69
Weighted average number of shares used in net loss per share calculations:
Basic (in shares)	4,501,206	3,755,564
Diluted (in shares)	4,501,206	3,755,564
Research and development revenue
Total revenue	$ 52,625	$ 19,754
Grant revenue
Total revenue	$ 4,681	$ 0

MTEM Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

Current assets:

Cash and cash equivalents

$ 11,523

$ 32,190

Marketable securities, current

28,859

Prepaid expenses

2,195

3,459

Grants revenue receivable

250

Other current assets

2,804

3,790

Total current assets

16,772

68,298

Operating lease right-of-use assets

9,161

11,132

Property and equipment, net

7,393

14,632

Other assets

2,057

3,486

Total assets

35,383

97,548

Current liabilities:

Accounts payable

1,523

504

Accrued liabilities

4,279

8,823

Deferred revenue, current

9,031

45,573

Other current liabilities

2,488

2,182

Total current liabilities

17,321

57,082

Deferred revenue, long-term

5,904

Long-term debt, net of current portion

36,168

Operating lease liabilities, long term portion

9,742

12,231

Contingent value right liability

2,702

Other liabilities

1,406

1,295

Total liabilities

31,171

112,680

Commitments and contingencies (Note 10)

Stockholders' equity/(deficit)

Preferred stock, $0.001 par value per share: Authorized: 2,000,000 shares as of December 31, 2023 and 2022; Issued and outstanding: 250 shares as of December 31, 2023 and 2022

Common stock, $0.001 par value per share: Authorized: 150,000,000 shares as of December 31, 2023 and 2022; Issued and outstanding: 5,374,268 shares as of December 31, 2023 and 3,756,711 shares as of December 31, 2022

^[1]

Additional paid-in capital

^[1]

457,099

429,698

Accumulated other comprehensive loss

(66)

Accumulated deficit

(452,892)

(444,768)

Total stockholders' equity/(deficit)

4,212

(15,132)

Total liabilities and stockholders' equity/(deficit)

$ 35,383

$ 97,548

[1]	Prior period amounts have been retrospectively adjusted for the 1-for-15 reverse stock split that was effective August 11, 2023 (see Note 1).

About Molecular Templates Inc

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company primarily develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

CEO	Dr. Eric E. Poma Ph.D.
WEBSITE	mtem.com
INDUSTRY	Biotechnology
EMPLOYEES	111

Molecular Templates Inc Frequently Asked Questions

What is the ticker symbol for Molecular Templates Inc? What does MTEM stand for in stocks?

MTEM is the stock ticker symbol of Molecular Templates Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Molecular Templates Inc (MTEM)?

As of Fri May 03 2024, market cap of Molecular Templates Inc is 11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MTEM stock?

You can check MTEM's fair value in chart for subscribers.

What is the fair value of MTEM stock?

You can check MTEM's fair value in chart for subscribers. The fair value of Molecular Templates Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Molecular Templates Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MTEM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Molecular Templates Inc a good stock to buy?

The fair value guage provides a quick view whether MTEM is over valued or under valued. Whether Molecular Templates Inc is cheap or expensive depends on the assumptions which impact Molecular Templates Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MTEM.

What is Molecular Templates Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, MTEM's PE ratio (Price to Earnings) is -1.35 and Price to Sales (PS) ratio is 0.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MTEM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Molecular Templates Inc's stock?

In the past 10 years, Molecular Templates Inc has provided -0.274 (multiply by 100 for percentage) rate of return.